266 related articles for article (PubMed ID: 14998581)
1. Stability and aerodynamic behaviour of glucocorticoid particles prepared by a supercritical fluids process.
Velaga SP; Bergh S; Carlfors J
Eur J Pharm Sci; 2004 Mar; 21(4):501-9. PubMed ID: 14998581
[TBL] [Abstract][Full Text] [Related]
2. Preparation and characterisation of hydrocortisone particles using a supercritical fluids extraction process.
Velaga SP; Ghaderi R; Carlfors J
Int J Pharm; 2002 Jan; 231(2):155-66. PubMed ID: 11755268
[TBL] [Abstract][Full Text] [Related]
3. Supercritical fluids crystallization of budesonide and flunisolide.
Velaga SP; Berger R; Carlfors J
Pharm Res; 2002 Oct; 19(10):1564-71. PubMed ID: 12425477
[TBL] [Abstract][Full Text] [Related]
4. Preparation of budesonide/gamma-cyclodextrin complexes in supercritical fluids with a novel SEDS method.
Toropainen T; Velaga S; Heikkilä T; Matilainen L; Jarho P; Carlfors J; Lehto VP; Järvinen T; Järvinen K
J Pharm Sci; 2006 Oct; 95(10):2235-45. PubMed ID: 16883551
[TBL] [Abstract][Full Text] [Related]
5. Experimental study of the GAS process for producing microparticles of beclomethasone-17,21-dipropionate suitable for pulmonary delivery.
Bakhbakhi Y; Charpentier PA; Rohani S
Int J Pharm; 2006 Feb; 309(1-2):71-80. PubMed ID: 16412594
[TBL] [Abstract][Full Text] [Related]
6. Supercritical fluid processing of proteins: lysozyme precipitation from aqueous solution.
Moshashaée S; Bisrat M; Forbes RT; Quinn EA; Nyqvist H; York P
J Pharm Pharmacol; 2003 Feb; 55(2):185-92. PubMed ID: 12631410
[TBL] [Abstract][Full Text] [Related]
7. Preparation of PLLA/PLGA microparticles using solution enhanced dispersion by supercritical fluids (SEDS).
Kang Y; Yin G; Ouyang P; Huang Z; Yao Y; Liao X; Chen A; Pu X
J Colloid Interface Sci; 2008 Jun; 322(1):87-94. PubMed ID: 18402971
[TBL] [Abstract][Full Text] [Related]
8. [Preparation of budesonide-poly (ethylene oxide) solid dispersions using supercritical carbon dioxide and in vitro evaluation].
Liu H; Pan WS; Zhou LL; Zhang ZH
Yao Xue Xue Bao; 2007 Feb; 42(2):206-10. PubMed ID: 17518053
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of supercritical fluid engineered budesonide powder for respiratory delivery using nebulisers.
Amani A; Chrystyn H; Clark BJ; Abdelrahim ME; York P
J Pharm Pharmacol; 2009 Dec; 61(12):1625-30. PubMed ID: 19958584
[TBL] [Abstract][Full Text] [Related]
10. Process parameters and morphology in puerarin, phospholipids and their complex microparticles generation by supercritical antisolvent precipitation.
Li Y; Yang DJ; Chen SL; Chen SB; Chan AS
Int J Pharm; 2008 Jul; 359(1-2):35-45. PubMed ID: 18440736
[TBL] [Abstract][Full Text] [Related]
11. Production of cromolyn sodium microparticles for aerosol delivery by supercritical assisted atomization.
Reverchon E; Adami R; Caputo G
AAPS PharmSciTech; 2007 Dec; 8(4):E114. PubMed ID: 18181535
[TBL] [Abstract][Full Text] [Related]
12. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
Marriott C; MacRitchie HB; Zeng XM; Martin GP
Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers.
Schiavone H; Palakodaty S; Clark A; York P; Tzannis ST
Int J Pharm; 2004 Aug; 281(1-2):55-66. PubMed ID: 15288343
[TBL] [Abstract][Full Text] [Related]
14. Optimisation of powders for pulmonary delivery using supercritical fluid technology.
Rehman M; Shekunov BY; York P; Lechuga-Ballesteros D; Miller DP; Tan T; Colthorpe P
Eur J Pharm Sci; 2004 May; 22(1):1-17. PubMed ID: 15113578
[TBL] [Abstract][Full Text] [Related]
15. The influence of humidity on the aerosolisation of micronised and SEDS produced salbutamol sulphate.
Young PM; Price R
Eur J Pharm Sci; 2004 Jul; 22(4):235-40. PubMed ID: 15196579
[TBL] [Abstract][Full Text] [Related]
16. Formation of indomethacin-saccharin cocrystals using supercritical fluid technology.
Padrela L; Rodrigues MA; Velaga SP; Matos HA; de Azevedo EG
Eur J Pharm Sci; 2009 Aug; 38(1):9-17. PubMed ID: 19477273
[TBL] [Abstract][Full Text] [Related]
17. Excipient-free nanoporous microparticles of budesonide for pulmonary delivery.
Nolan LM; Tajber L; McDonald BF; Barham AS; Corrigan OI; Healy AM
Eur J Pharm Sci; 2009 Jul; 37(5):593-602. PubMed ID: 19463948
[TBL] [Abstract][Full Text] [Related]
18. Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients.
Minne A; Boireau H; Horta MJ; Vanbever R
Eur J Pharm Biopharm; 2008 Nov; 70(3):839-44. PubMed ID: 18620052
[TBL] [Abstract][Full Text] [Related]
19. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
20. Influence of process parameters in the ASES process on particle properties of budesonide for pulmonary delivery.
Steckel H; Pichert L; Müller BW
Eur J Pharm Biopharm; 2004 May; 57(3):507-12. PubMed ID: 15093600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
